Skip to main content
Equibles
TRVI logo

TRVI · Trevi Therapeutics, Inc. · Webcasts, Transcripts & Audio

Track TRVI — free

Use TRVI with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research TRVI.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$13.72 -0.19 (-1.37%) At close · Oct 5
Russell 2000 member Rebalance outlook locked
Market Cap
$2.05B
Shares
142.48M
Volume · Oct 5 1.72M Avg daily vol (3M) 1.92M

Trevi Therapeutics, Inc. Webcasts

Earnings calls, investor updates, investor days and conferences for Trevi Therapeutics, Inc. (TRVI), with available transcripts, audio replays and slides. Earnings calls also include available highlights, earnings releases and periodic filings.

Pull transcripts and briefs through the earnings call transcript API or MCP →
Conference
Investor event
2026-09-16
Trevi Therapeutics, Inc. (TRVI) September 2026 Conference
No reported result — non-financial event
Audio Transcript Slides
Conference
Investor event
2026-09-16
Trevi Therapeutics, Inc. (TRVI) September 2026 Conference
No reported result — non-financial event
Audio Transcript Slides
Conference
Investor event
2026-09-11
Trevi Therapeutics, Inc. (TRVI) September 2026 Conference
No reported result — non-financial event
Audio Transcript Slides
Earnings call
FY26 · Q2
2026-08-06
Trevi Therapeutics, Inc. (TRVI) Q2 2026 Earnings Call Transcript
Positive tone Clinical trial execution and enrollment Non-IPF ILD chronic cough program LAKE Phase 2B trial in RCC and SSRE
Diluted EPS
$-0.11
Audio Transcript Slides 8-K10-Q
Capital Markets Day
Investor event
2026-05-07
Trevi Therapeutics, Inc. (TRVI) May 2026 Capital Markets Day
No reported result — non-financial event
Audio Transcript Slides
Earnings call
FY26 · Q1
2026-05-05
Trevi Therapeutics, Inc. (TRVI) Q1 2026 Earnings Call Transcript
Confident tone Refractory chronic cough Phase IIb Competitive landscape and P2X3 Non-IPF-ILD chronic cough program
Diluted EPS
$-0.09
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q4
2026-03-17
Trevi Therapeutics, Inc. (TRVI) Q4 2025 Earnings Call Transcript
Confident tone FDA alignment and regulatory progress IPF-related chronic cough (Heduvio) Phase III program Non-IPF ILD chronic cough indication
Results not yet reported
Audio Transcript Slides 8-K10-K
Conference
Investor event
2026-03-11
Trevi Therapeutics, Inc. (TRVI) March 2026 Conference Transcript
No reported result — non-financial event
Audio Transcript Slides
Earnings call
FY25 · Q3
2025-11-13
Trevi Therapeutics, Inc. (TRVI) Q3 2025 Earnings Call Transcript
Confident tone Regulatory milestones and FDA interactions Refractory chronic cough (RCC) program Safety profile and tolerability of Nalbuphine ER
Diluted EPS
$-0.08
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q2
2025-08-07
Trevi Therapeutics, Inc. (TRVI) Q2 2025 Earnings Call Transcript
Confident tone IPF cough Phase III planning CORAL Phase IIb results Refractory chronic cough program
Diluted EPS
$-0.09
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q1
2025-06-02
Trevi Therapeutics, Inc. (TRVI) Q1 2025 Earnings Call Transcript
Confident tone CORAL Phase 2b IPF Trial FDA Regulatory Engagement RIVER Phase 2a RCC Data
Diluted EPS
$-0.09
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q4
2025-03-18
Trevi Therapeutics, Inc. (TRVI) Q4 2024 Earnings Call Transcript
Confident tone RCC (refractory chronic cough) opportunity Positive clinical readouts across Haduvio program IPF chronic cough lead indication and CORAL Phase 2b
Results not yet reported
Audio Transcript Slides 8-K10-K
Earnings call
FY24 · Q3
2024-11-06
Trevi Therapeutics, Inc. (TRVI) Q3 2024 Earnings Call Transcript
Positive tone HAP study and DEA scheduling risk IPF chronic cough Phase 2b CORAL trial New CDO Jim Cassella
Diluted EPS
$-0.13
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q2
2024-08-08
Trevi Therapeutics, Inc. (TRVI) Q2 2024 Earnings Call Transcript
Positive tone RIVER Phase 2a RCC Trial CORAL Phase 2b IPF Chronic Cough Trial Supportive Studies (HAP and Respiratory Physiology)
Diluted EPS
$-0.12
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q1
2024-05-07
Trevi Therapeutics, Inc. (TRVI) Q1 2024 Earnings Call Transcript
Confident tone RIVER Phase IIa trial in refractory chronic cough CORAL Phase IIb trial in IPF chronic cough Human abuse potential study (HAP)
Diluted EPS
$-0.11
Audio Transcript Slides 8-K10-Q
Earnings call
FY23 · Q4
2024-03-20
Trevi Therapeutics, Inc. (TRVI) Q4 2023 Earnings Call Transcript
Confident tone Phase 2b CORAL trial in IPF chronic cough Phase 2a RIVER trial in RCC Human Abuse Potential (HAP) study
Results not yet reported
Audio Transcript Slides 8-K10-K
Earnings call
FY23 · Q3
2023-11-09
Trevi Therapeutics, Inc. (TRVI) Q3 2023 Earnings Call Transcript
Diluted EPS
$-0.08
Audio Transcript Slides 8-K10-Q
Earnings call
FY23 · Q2
2023-08-10
Trevi Therapeutics, Inc. (TRVI) Q2 2023 Earnings Call Transcript
Diluted EPS
$-0.07
Audio Transcript Slides 8-K10-Q
Earnings call
FY23 · Q1
2023-05-11
Trevi Therapeutics, Inc. (TRVI) Q1 2023 Earnings Call Transcript
Diluted EPS
$-0.06
Audio Transcript Slides 8-K10-Q
Earnings call
FY22 · Q4
2023-03-16
Trevi Therapeutics, Inc. (TRVI) Q4 2022 Earnings Call Transcript
Results not yet reported
Audio Transcript Slides 8-K10-K
Earnings call
FY22 · Q3
2022-11-10
Trevi Therapeutics, Inc. (TRVI) Q3 2022 Earnings Call Transcript
Diluted EPS
$-0.12
Audio Transcript Slides 8-K10-Q
Earnings call
FY22 · Q2
2022-08-11
Trevi Therapeutics, Inc. (TRVI) Q2 2022 Earnings Call Transcript
Diluted EPS
$-0.14
Audio Transcript Slides 8-K10-Q
Earnings call
FY22 · Q1
2022-05-12
Trevi Therapeutics, Inc. (TRVI) Q1 2022 Earnings Call Transcript
Diluted EPS
$-0.24
Audio Transcript Slides 8-K10-Q
Earnings call
FY21 · Q4
2022-03-17
Trevi Therapeutics, Inc. (TRVI) Q4 2021 Earnings Call Transcript
Results not yet reported
Audio Transcript Slides 8-K10-K
Earnings call
FY21 · Q3
2021-11-10
Trevi Therapeutics, Inc. (TRVI) Q3 2021 Earnings Call Transcript
Diluted EPS
$-0.34
Audio Transcript Slides 8-K10-Q
Earnings call
FY21 · Q2
2021-08-12
Trevi Therapeutics, Inc. (TRVI) Q2 2021 Earnings Call Transcript
Diluted EPS
$-0.49
Audio Transcript Slides 8-K10-Q
Earnings call
FY21 · Q1
2021-05-13
Trevi Therapeutics, Inc. (TRVI) Q1 2021 Earnings Call Transcript
Results not yet reported
Audio Transcript Slides 8-K10-Q
Earnings call
FY20 · Q4
2021-03-25
Trevi Therapeutics, Inc. (TRVI) Q4 2020 Earnings Call Transcript
Results not yet reported
Audio Transcript Slides 8-K10-K
Earnings call
FY20 · Q3
2020-11-12
Trevi Therapeutics, Inc. (TRVI) Q3 2020 Earnings Call Transcript
Results not yet reported
Audio Transcript Slides 8-K10-Q
Earnings call
FY20 · Q2
2020-08-13
Trevi Therapeutics, Inc. (TRVI) Q2 2020 Earnings Call Transcript
Results not yet reported
Audio Transcript Slides 8-K10-Q
Showing 1–30 of 30 webcasts
Key facts CIK 1563880 CUSIP 89532M101 13F (30d) 4 filings 4 filers Visit website Investor relations